ELUXADOLINE Drug Patent Profile

Which patents cover Eluxadoline, and what generic alternatives are available?

Eluxadoline is a drug marketed by Zydus Pharms and is included in one NDA.

The generic ingredient in ELUXADOLINE is eluxadoline. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eluxadoline profile page.

Summary for ELUXADOLINE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ELUXADOLINE

Paragraph IV (Patent) Challenges for ELUXADOLINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIBERZI	Tablets	eluxadoline	75 mg and 100 mg	206940	6	2019-05-28

US Patents and Regulatory Information for ELUXADOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	ELUXADOLINE	eluxadoline	TABLET;ORAL	213522-001	Mar 14, 2025		DISCN	No	No
Zydus Pharms	ELUXADOLINE	eluxadoline	TABLET;ORAL	213522-002	Mar 14, 2025		DISCN	No	No

Eluxadoline: Market Landscape and Patent Strategy Analysis

Last updated: February 19, 2026

Eluxadoline, marketed as Viberzi, is a first-in-class oral $\mu$-opioid receptor agonist and $\kappa$-opioid receptor antagonist, and a $\delta$-opioid receptor agonist. It is approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Its unique dual mechanism of action targets multiple receptors in the gut to reduce visceral sensitivity and intestinal motility.

What is Eluxadoline's Approved Indication and Mechanism of Action?

Eluxadoline is approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. The drug's mechanism of action involves binding to multiple opioid receptors in the enteric nervous system. Specifically, it acts as a $\mu$-opioid receptor agonist, a $\kappa$-opioid receptor antagonist, and a $\delta$-opioid receptor agonist [1]. This multi-receptor activity results in reduced intestinal motility and visceral sensitivity, thereby alleviating the symptoms of IBS-D, including abdominal pain and diarrhea.

Who Developed and Markets Eluxadoline?

Eluxadoline was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is currently marketed under the brand name Viberzi [2]. The development and commercialization strategy involved extensive clinical trials to establish efficacy and safety for the target patient population.

What is the Market Size and Potential for IBS-D Treatments?

The global market for irritable bowel syndrome (IBS) treatments is substantial. IBS affects an estimated 10% to 15% of the global population, with IBS-D being a significant subtype. Market research reports estimate the global IBS market to be valued in the billions of dollars, with projected growth driven by increasing awareness, diagnosis rates, and the availability of new therapeutic options [3]. Eluxadoline competes in this market with other approved therapies and over-the-counter remedies.

What is the Patent Landscape for Eluxadoline?

The patent landscape for eluxadoline is crucial for understanding its market exclusivity and the potential for generic competition. The primary patents cover the compound itself, its synthesis, and its therapeutic uses.

Key Patents and Expiry Dates

The foundational patents for eluxadoline have been central to its market protection.

• Composition of Matter Patent: The patent covering the eluxadoline molecule itself is critical. U.S. Patent No. 7,754,741, titled "Substituted-(1-phenyl-4-piperidinyl)alkanamides," claims the compound eluxadoline. This patent initially had an expiry date of May 1, 2026, with potential for patent term extension (PTE) [4].
• Method of Use Patents: Additional patents cover specific methods of using eluxadoline to treat IBS-D. For instance, U.S. Patent No. 9,000,045, also held by Janssen, covers methods of treating IBS-D. This patent has an expiry date in 2031 [4].
• Formulation Patents: Patents related to specific pharmaceutical formulations of eluxadoline may extend market exclusivity for particular dosage forms or delivery methods.

The interplay of these patents, including their expiry dates and any granted patent term extensions or data exclusivity periods, dictates the duration of market exclusivity for branded Viberzi.

What are the Key Competitive Therapies for IBS-D?

Eluxadoline faces competition from a range of therapeutic agents, including both prescription and over-the-counter options.

Prescription Therapies

• Rifaximin (Xifaxan): A non-absorbable antibiotic used to reduce bacterial overgrowth in the gut, which can contribute to IBS symptoms. Approved for IBS-D in certain patient populations.
• Loperamide: An over-the-counter opioid-receptor agonist that slows gut motility and reduces diarrhea. While effective for symptom control, it does not address the underlying visceral hypersensitivity associated with IBS.
• Diphenoxylate/Atropine (Lomotil): Another prescription antidiarrheal that works by slowing gut motility.
• Alosetron (Lotronex): A selective 5-HT3 receptor antagonist. Its use is restricted due to potential serious gastrointestinal side effects, including ischemic colitis, and requires a Risk Evaluation and Mitigation Strategy (REMS) program.
• Ondansetron: A 5-HT3 receptor antagonist sometimes used off-label for diarrhea.

Over-the-Counter (OTC) Therapies

• Psyllium: A bulk-forming laxative that can help regulate bowel movements.
• Antispasmodics: Medications like dicyclomine and hyoscyamine can help relieve abdominal cramping.
• Dietary Modifications: Various dietary approaches, such as the low-FODMAP diet, are often recommended by healthcare professionals.

Eluxadoline differentiates itself through its novel dual mechanism targeting both motility and visceral sensitivity, and its oral, once-daily dosing regimen.

What is the Regulatory Status and Post-Approval History of Eluxadoline?

Eluxadoline received FDA approval on May 27, 2015, for the treatment of IBS-D in adult patients [5]. The drug's approval was based on data from two Phase III clinical trials (IMPROVE 1 and IMPROVE 2) which demonstrated statistically significant improvements in abdominal pain and stool consistency compared to placebo [1].

Post-approval, eluxadoline has undergone monitoring for safety and efficacy. A notable event was the U.S. Postal Service (USPS) filing a citizen petition requesting the FDA to change Viberzi's labeling to include a boxed warning and to add contraindications related to patients without a gallbladder or with a history of pancreatitis or severe liver disease [6]. The FDA reviewed the petition and determined that while eluxadoline has a risk of sphincter of Oddi spasm, which can lead to pancreatitis and other serious conditions, particularly in patients without a gallbladder or with other risk factors, the existing prescribing information adequately communicates these risks. The FDA did not require labeling changes as a result of the USPS petition, but it underscores the importance of patient selection and contraindications [6].

What is the Commercial Performance and Market Share of Eluxadoline?

Viberzi has established a market presence in the IBS-D treatment landscape. While specific, real-time market share data is proprietary and fluctuates, clinical trial data and prescription trends indicate its significant adoption.

• Sales Data: Johnson & Johnson reported net sales for Viberzi. For instance, in 2022, Viberzi generated approximately $465 million in net sales globally [7]. This figure represents a key indicator of its commercial success and patient uptake.
• Prescription Volume: Prescription data from market analytics firms typically show Viberzi as one of the leading branded prescription therapies for IBS-D. The volume of prescriptions is influenced by physician prescribing habits, formulary access, and patient adherence.

The commercial performance is a direct reflection of the drug's perceived clinical benefit, safety profile, and the effectiveness of the marketing and sales strategies employed by Janssen.

What is the Litigation and Generic Competition Landscape?

The patent expiry dates for eluxadoline's core patents are critical for assessing the timeline for generic entry.

• Patent Challenges: Pharmaceutical companies often face patent litigation as expiry dates approach, with generic manufacturers seeking to invalidate existing patents or design around them. As of the latest available information, there have been ongoing legal proceedings concerning the patents protecting eluxadoline. Generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) challenging the validity and enforceability of certain patents.
• Generic Entry Timeline: The primary composition of matter patent (U.S. Patent No. 7,754,741) has an original expiry in 2026. However, the actual date of generic entry can be influenced by:
  • Patent Term Extension (PTE): The FDA can grant PTE to compensate for patent term lost during regulatory review.
  • Inter Partes Review (IPR): Challenges to patent validity through the USPTO.
  • Litigation Outcomes: Court decisions on patent infringement and validity.
  • Paragraph IV Certifications: Generic companies can challenge patents, and if successful, may gain a 180-day exclusivity period for being the first to file a non-infringed ANDA.

The timing of potential generic entry for eluxadoline will significantly impact the market dynamics, leading to price erosion for the branded product and potentially increased patient access. As of late 2023/early 2024, the exact timing of the first generic launch remains subject to ongoing litigation and regulatory review.

What are the Future Prospects and Potential for Eluxadoline?

The future prospects for eluxadoline are tied to its established market position, the ongoing management of its safety profile, and the eventual advent of generic competition.

• Continued IBS-D Market Penetration: As awareness of IBS-D as a distinct condition grows and physicians become more familiar with eluxadoline's unique mechanism, there is potential for continued penetration within its approved indication.
• Lifecycle Management: Janssen may explore lifecycle management strategies, such as new formulations or combination therapies, although such efforts are often complex and time-consuming.
• Impact of Generic Competition: The most significant factor influencing future prospects will be the introduction of generic versions. This will likely lead to a substantial decrease in net revenue for the branded product as price competition intensifies. The rate of generic adoption will depend on formulary status, physician familiarity with generics, and patient cost-sharing.
• Potential for Label Expansions: While not currently on the horizon, any investigation into new indications or patient sub-populations could alter its long-term trajectory. However, the regulatory pathway for new indications is rigorous and requires extensive clinical development.

The primary challenge will be navigating the post-patent exclusivity period effectively, as market dynamics shift with the availability of lower-cost generic alternatives.

Key Takeaways

• Eluxadoline (Viberzi) is a prescription medication approved for IBS-D, employing a unique dual opioid receptor mechanism.
• Its primary composition of matter patent is scheduled to expire in 2026, with other method of use patents extending further.
• The IBS-D market is substantial, with eluxadoline competing against various prescription and OTC therapies.
• The drug's safety profile, particularly concerning patients without a gallbladder, has been subject to regulatory review.
• Viberzi generated approximately $465 million in net sales globally in 2022, indicating strong commercial performance.
• Potential generic entry is anticipated around the expiry of key patents, which will fundamentally alter its market exclusivity and pricing.
• Future prospects are dominated by the anticipated impact of generic competition, leading to a shift in market dynamics and revenue generation for the branded product.

Frequently Asked Questions

1. When is the primary patent for eluxadoline expected to expire? The primary composition of matter patent (U.S. Patent No. 7,754,741) for eluxadoline is expected to expire on May 1, 2026, though this can be subject to Patent Term Extension and ongoing litigation.

2. What are the main safety concerns associated with eluxadoline? The main safety concerns include the risk of sphincter of Oddi spasm, which can lead to pancreatitis and other serious gastrointestinal conditions, particularly in patients without a gallbladder or with a history of pancreatitis or severe liver disease.

3. What was the net sales revenue for Viberzi in the most recent reported year? Viberzi generated approximately $465 million in net sales globally in 2022.

4. Which other medications are considered key competitors to eluxadoline in the IBS-D market? Key competitors include rifaximin (Xifaxan), loperamide, diphenoxylate/atropine (Lomotil), and alosetron (Lotronex), as well as various over-the-counter options.

5. What is the expected impact of generic eluxadoline on the market? The introduction of generic eluxadoline is expected to lead to significant price erosion for the branded product and increased competition, potentially improving patient access through lower costs.

Citations

[1] Janssen Pharmaceuticals. (2015). Viberzi (eluxadoline) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206276s000lbl.pdf

[2] Johnson & Johnson. (2015). Janssen Receives FDA Approval for Viberzi™ (eluxadoline), a Novel Oral Treatment for Adults with Irritable Bowel Syndrome with Diarrhea (IBS-D). [Press Release].

[3] Grand View Research. (2023). Irritable Bowel Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030.

[4] U.S. Patent and Trademark Office. (Accessed 2023). Patent Search Database.

[5] U.S. Food and Drug Administration. (2015, May 27). FDA approves Viberzi for treatment of irritable bowel syndrome with diarrhea. [Press Release].

[6] U.S. Food and Drug Administration. (2018). Citizen Petition: Request to revise labeling for Viberzi (eluxadoline) and add contraindications.

[7] Johnson & Johnson. (2023). 2022 Annual Report on Form 10-K.